Matthew D. Hellmann
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 183
- Cancer Immunotherapy and Biomarkers 149
- Lung Cancer Research Studies 36
- Colorectal Cancer Treatments and Studies 26
- CAR-T cell therapy research 20
-
- Lung Cancer Treatments and Mutations 88
- Lung Cancer Diagnosis and Treatment 22
- Co-authors
- Michael A. Postow (12 shared papers)Robert Sidlow (1 shared paper)Adam J. Schoenfeld (13 shared papers)Mark G. Kris (45 shared papers)Jamie E. Chaft (34 shared papers)Jedd D. Wolchok (19 shared papers)Hira Rizvi (49 shared papers)Scott Antonia (24 shared papers)
- Journals
- Journal of Clinical Oncology (77 papers)Annals of Oncology (30 papers)Journal of Thoracic Oncology (28 papers)Clinical Cancer Research (11 papers)Cancer Research (9 papers)
- Partner nations
- United StatesSpainGermany
In The Last Decade
Matthew D. Hellmann
227 papers receiving 21.8k citations
Matthew D. Hellmann's Hit Papers
Peers
Comparison fields: 5 of 146
- Oncology 14.1k
- Pulmonary and Respiratory Medicine 6.5k
- Immunology 4.3k
- Cancer Research 2.1k
- Pathology and Forensic Medicine 989
Countries citing papers authored by Matthew D. Hellmann
This map shows the geographic impact of Matthew D. Hellmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Hellmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Hellmann more than expected).
Fields of papers citing papers by Matthew D. Hellmann
This network shows the impact of papers produced by Matthew D. Hellmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Hellmann. The network helps show where Matthew D. Hellmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthew D. Hellmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 231 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Immune-Related Adverse Events Associated with Immune Checkpoint Blockade Hit paper breakdown → | 2018 | 3348 |
| 2 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 1621 |
| 3 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 729 |
| 4 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Hit paper breakdown → | 2016 | 706 |
| 5 | Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 680 |
| 6 | Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer Hit paper breakdown → | 2018 | 653 |
| 7 | Acquired Resistance to Immune Checkpoint Inhibitors Hit paper breakdown → | 2020 | 635 |
| 8 | Chromatin states define tumour-specific T cell dysfunction and reprogramming Hit paper breakdown → | 2017 | 625 |
| 9 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study Hit paper breakdown → | 2018 | 545 |
| 10 | Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer Hit paper breakdown → | 2016 | 495 |
| 11 | A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 455 |
| 12 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint Hit paper breakdown → | 2014 | 427 |
| 13 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 399 |
| 14 | 2016 | 352 | |
| 15 | 2017 | 350 | |
| 16 | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets Hit paper breakdown → | 2016 | 334 |
| 17 | 2017 | 322 | |
| 18 | 2016 | 315 | |
| 19 | 2019 | 315 | |
| 20 | 2019 | 275 |
About Matthew D. Hellmann
Matthew D. Hellmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Molecular Biology, having authored 231 papers that have together received 21.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (149 papers), Lung Cancer Treatments and Mutations (88 papers), Cancer Genomics and Diagnostics (49 papers), Lung Cancer Research Studies (36 papers), Colorectal Cancer Treatments and Studies (26 papers), Lung Cancer Diagnosis and Treatment (22 papers), CAR-T cell therapy research (20 papers) and Immunotherapy and Immune Responses (16 papers). The work is most often cited by research in Oncology (14.1k citations), Pulmonary and Respiratory Medicine (6.5k citations), Immunology (4.3k citations), Cancer Research (2.1k citations) and Pathology and Forensic Medicine (989 citations). Matthew D. Hellmann has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Michael A. Postow, Robert Sidlow, Adam J. Schoenfeld, Mark G. Kris, Jamie E. Chaft, Jedd D. Wolchok, Hira Rizvi, Scott Antonia, Naiyer A. Rizvi and Gregory J. Riely. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Clinical Cancer Research and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.